

## ANSWERING REVIEWERS



March 12, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 8925-review.doc).

**Title:** FoxM1 as a new therapeutic target for cancer drug therapy

**Author:** Xinsen Xu, Yong Wan, Kai Qu, Sinan Liu, Lingqiang Zhang, Zhixin Wang, Jingyao Zhang, Minghui Tai, Yafeng Dong, Chang Liu

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 8925

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Reviewer 1:

1) Table 1 only lists the names of cancer, which are the same as those indicated in the main body of manuscript. Therefore, it seems unnecessary. 2) Tables 2 only adds a little information to Figure 1. I feel that Figure 1 and Table 2 should be revised. 3) There are a lot of abbreviations, but some of them were not spelled out.

**Answer:** Thanks for your kindly suggestions.

1) As Table 1 has listed series kinds of cancer, it is too much for the main body of the manuscript, if we put it all into the manuscript. So we think it is better to be listed in Table, which is meanwhile more obvious for readers.

2) Table 2 and Figure 1 is of the same topic. Table 2 summarised the main information of the references included in Figure 1, which supplement Figure 1, as a system-review.

3) Sorry for our mistakes. We have checked all the abbreviations, and have revised them in the manuscript.

(2) Reviewer 2:

1) Throughout the manuscript, tumour entities are not given in detail. In order to establish personalized oncology, recognition of tumour entity and sub-entity is crucial. For example, the terms lung cancer or thyroid cancer includes several other entities which should be addressed concerning FoxM1. 2) As stated in Table 2, FoxM1 expression in tumours is preferentially characterized with immunohistochemistry. In the review, staining procedures, use of different anti-FoxM1 antibodies, and algorithms to judge staining results (biopsy/ surgical resection) should be critically addressed.

**Answer:** Thanks for your kindly suggestions.

1) it's true that the tumor entity and sub-entity is crucial. However, if we listed the sub-entity, considering the so many kinds of tumors we mentioned, we're afraid that it may confuse the readers to some extent. So, we just used the entity name, such as lung cancer, and liver cancer, which is more attractive and convenient to comprehend by readers. If some of the readers are interested in the specific cancer, we also listed the reference number, so they can get access to the specific information easily.


2) As we have shown in Table 2, that all the studies use immunohistochemistry to study the expression of FoxM1. The anti-FoxM1 antibodies are almost the same, as we have also done some

research on FoxM1 (PMID: 23359173, 23262037, 20154714). We didn't list the differences such as the providing companies. The other algorithms are almost the same, which is the typical immunohistochemistry staining.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Chang Liu', is shown on a light background.

Chang Liu, MD, PhD

Dept. of Hepatobiliary Surgery

School of Medicine, Xi'an Jiaotong University

Fax: +86-029-85324746

E-mail: liuchangdoctor@163.com